Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Stopped early · Phase 1/Phase 2

Conditions studied: Tumors, Unknown Primary Tumors, Adenocarcinoma

In brief

This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.

Key facts

Study ID
NCT00201734
Run by
Ohio State University Comprehensive Cancer Center
People needed
57
Starts
2005-06-01
Expected to finish
2013-06-01
Last updated by the study team
2016-09-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.